Introduction: Acute bronchiolitis may lead to hospitalization with some morbidity and mortality. Finding some agents to reduce severity of disease can improve morbidity and mortality. Objectives & (hypothesis OR questions): To evaluate the effect of zinc sulfate in improving the clinical manifestations of acute bronchiolitis in children younger than 2 years old. Materials & Methods: It was a double blind pilot trial on patients, age 2 months to 23 months at Ghaem and Dr. Sheikh hospitals in Mashhad from Jan 2008 to March 2009. Patients randomly divided into two groups: case group who took oral zinc sulfate 1% (1 CC per kg in infants below 1 year old and 10 CC (20 mg of elemental zinc) for children above 1 year old during hospitalization and controls who received placebo. Bottles of drugs were similar in shape and size. Inclusion criteria: Age 2 months to 23 months, first attack of wheezing. Exclusion criteria: Any history of previous wheezing attack(s), congenital heart disease, severe malnutrition, any history of taking zinc sulfate last month and pneumonia. Clinical manifestation including tachypnea, wheezing , cyanosis, intercostal and subcostal retractions and nasal flaring at admission, 24 , 48, and 72 hours after hospitalization were assessed. Recovery from acute bronchiolitis was defined as; complete disappearance of tachypnea, intercostal and subcostal retractions , wheezing and cyanosis